StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 17:12:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form PRE 14C Curanex Pharmaceuticals For: Jun 18 http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html si-local-file:///var/storage/secattach/20260618/26667217.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html Thu, 18 Jun 2026 17:12:00 -0400 CURX O.48073990 Form PRE 14C Curanex Pharmaceuticals For: Jun 18 http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html si-local-file:///var/storage/secattach/20260618/26667217.html http://www.streetinsider.com/SEC+Filings/Form++PRE+14C++++Curanex+Pharmaceuticals+++For%3A+Jun+18/26667217.html Thu, 18 Jun 2026 17:12:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 14 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html si-local-file:///var/storage/secattach/20260514/26491326.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html Thu, 14 May 2026 09:16:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 14 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html si-local-file:///var/storage/secattach/20260514/26491326.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+14/26491326.html Thu, 14 May 2026 09:16:00 -0400 CURX O.48073990 Curanex completes manufacturing milestones for Phyto-N drug candidate http://www.streetinsider.com/Corporate+News/Curanex+completes+manufacturing+milestones+for+Phyto-N+drug+candidate/26490907.html <p>Curanex Pharmaceuticals Inc. (NASDAQ: CURX) reported progress on its lead drug candidate Phyto-N during the first quarter of 2026, completing manufacturing and toxicology studies ahead of a planned FDA submission.</p><p>The company completed production of a Good Manufacturing Practice-compliant pilot-scale batch of Phyto-N in February 2026. The material will support toxicology and pharmacokinetic studies required for an Investigational New Drug application planned for the fourth quarter of 2026.</p><p>In March 2026, Curanex completed a 28-day toxicology study of Phyto-N in rats and dogs. The company reported no treatment-related adverse findings at any dose level in either species, including at the maximum feasible http://www.streetinsider.com/Corporate+News/Curanex+completes+manufacturing+milestones+for+Phyto-N+drug+candidate/26490907.html Thu, 14 May 2026 08:55:21 -0400 CURX Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Press+Releases/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html <p align="center"><i>Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis</i></p> <p align="center"><i>Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated wasting condition with no FDA-approved therapies specifically indicated for the condition</i></p> <p align="justify"><b>Jericho, New York, May 14, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today provided a first quarter 2026 business update highlighting continued progress with Phyto-N, the Company’s lead drug candidate.</p> <p align="justify">Curanex is http://www.streetinsider.com/Globe+Newswire/Curanex+Reports+First+Quarter+2026+Business+Progress+as+Phyto-N+Advances+Toward+Planned+FDA+Submission/26490872.html Thu, 14 May 2026 08:53:00 -0400 A.02297628 A.06822034 CURX O.20026344 O.48073990 O.59983732 Form 10-Q Curanex Pharmaceuticals For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html si-local-file:///var/storage/secattach/20260514/26490826.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html Thu, 14 May 2026 08:48:00 -0400 CURX O.48073990 Form 10-Q Curanex Pharmaceuticals For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html si-local-file:///var/storage/secattach/20260514/26490826.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Curanex+Pharmaceuticals+++For%3A+Mar+31/26490826.html Thu, 14 May 2026 08:48:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 05 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html si-local-file:///var/storage/secattach/20260507/26451049.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html Thu, 07 May 2026 11:45:00 -0400 CURX O.48073990 Form 8-K Curanex Pharmaceuticals For: May 05 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html si-local-file:///var/storage/secattach/20260507/26451049.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Curanex+Pharmaceuticals+++For%3A+May+05/26451049.html Thu, 07 May 2026 11:45:00 -0400 CURX O.48073990 Curanex reports patient cases for cancer cachexia candidate http://www.streetinsider.com/Corporate+News/Curanex+reports+patient+cases+for+cancer+cachexia+candidate/26286202.html <p>Curanex Pharmaceuticals Inc. (NASDAQ: CURX) reported five additional patient cases involving its lead drug candidate for cancer cachexia and advanced cancer supportive care, according to a company statement.</p><p>The cases include patients with advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease. According to patient accounts cited by the company, individuals reported improvements in appetite, mobility, and overall condition after taking the product.</p><p>The company highlighted a 52-year-old male patient with advanced thymic carcinoma who had an estimated survival of one month. According to the patient account, after approximately 20 days of treatment, pain disappeared http://www.streetinsider.com/Corporate+News/Curanex+reports+patient+cases+for+cancer+cachexia+candidate/26286202.html Wed, 08 Apr 2026 07:47:58 -0400 CURX Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline http://www.streetinsider.com/Press+Releases/Curanex+Highlights+Five+Additional+Patient+Cases+Further+Supporting+the+Potential+of+Its+Lead+Candidate+in+Cancer+Cachexia%2C+Advanced+Cancer+Supportive+Care+and+Severe+Systemic+Decline/26286199.html <p align="justify"><i>Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease</i></p> <p align="justify"><i>According to patient accounts, multiple critically ill patients with very poor prognoses reported meaningful improvements in functional status, appetite, mobility, and overall condition after taking the Company's product</i></p> <p align="justify"><b>Jericho, New York, April 08, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today highlighted five additional patient cases that management believes further http://www.streetinsider.com/Press+Releases/Curanex+Highlights+Five+Additional+Patient+Cases+Further+Supporting+the+Potential+of+Its+Lead+Candidate+in+Cancer+Cachexia%2C+Advanced+Cancer+Supportive+Care+and+Severe+Systemic+Decline/26286199.html Wed, 08 Apr 2026 07:47:00 -0400 A.02297628 A.32727947 CURX O.00048394 O.48073990 O.59983732 Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline http://www.streetinsider.com/Press+Releases/Curanex+Highlights+Five+Additional+Patient+Cases+Further+Supporting+the+Potential+of+Its+Lead+Candidate+in+Cancer+Cachexia%2C+Advanced+Cancer+Supportive+Care+and+Severe+Systemic+Decline/26286199.html <p align="justify"><i>Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease</i></p> <p align="justify"><i>According to patient accounts, multiple critically ill patients with very poor prognoses reported meaningful improvements in functional status, appetite, mobility, and overall condition after taking the Company's product</i></p> <p align="justify"><b>Jericho, New York, April 08, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today highlighted five additional patient cases that management believes further http://www.streetinsider.com/Press+Releases/Curanex+Highlights+Five+Additional+Patient+Cases+Further+Supporting+the+Potential+of+Its+Lead+Candidate+in+Cancer+Cachexia%2C+Advanced+Cancer+Supportive+Care+and+Severe+Systemic+Decline/26286199.html Wed, 08 Apr 2026 07:47:00 -0400 A.02297628 A.32727947 CURX O.00048394 O.48073990 O.59983732 Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline http://www.streetinsider.com/Press+Releases/Curanex+Highlights+Five+Additional+Patient+Cases+Further+Supporting+the+Potential+of+Its+Lead+Candidate+in+Cancer+Cachexia%2C+Advanced+Cancer+Supportive+Care+and+Severe+Systemic+Decline/26286199.html <p align="justify"><i>Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease</i></p> <p align="justify"><i>According to patient accounts, multiple critically ill patients with very poor prognoses reported meaningful improvements in functional status, appetite, mobility, and overall condition after taking the Company's product</i></p> <p align="justify"><b>Jericho, New York, April 08, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX)</b> ("Curanex" or the "Company"), a pharmaceutical development company focused on advancing therapeutic assets for serious diseases with significant unmet medical need, today highlighted five additional patient cases that management believes further http://www.streetinsider.com/Press+Releases/Curanex+Highlights+Five+Additional+Patient+Cases+Further+Supporting+the+Potential+of+Its+Lead+Candidate+in+Cancer+Cachexia%2C+Advanced+Cancer+Supportive+Care+and+Severe+Systemic+Decline/26286199.html Wed, 08 Apr 2026 07:47:00 -0400 A.02297628 A.32727947 CURX O.00048394 O.48073990 O.59983732